BEAT vs. XAIR, APYX, DXR, CTSO, AMIX, HSAQ, CTCX, SRTS, NSPR, and LUCD
Should you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include Beyond Air (XAIR), Apyx Medical (APYX), Daxor (DXR), Cytosorbents (CTSO), Autonomix Medical (AMIX), Health Sciences Acquisitions Co. 2 (HSAQ), Carmell (CTCX), Sensus Healthcare (SRTS), InspireMD (NSPR), and Lucid Diagnostics (LUCD). These companies are all part of the "surgical & medical instruments" industry.
Beyond Air (NASDAQ:XAIR) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.
Beyond Air's return on equity of -106.91% beat BioTelemetry's return on equity.
31.5% of Beyond Air shares are held by institutional investors. Comparatively, 7.8% of BioTelemetry shares are held by institutional investors. 19.0% of Beyond Air shares are held by insiders. Comparatively, 7.3% of BioTelemetry shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Beyond Air currently has a consensus target price of $11.25, suggesting a potential upside of 857.45%. BioTelemetry has a consensus target price of $6.78, suggesting a potential upside of 230.49%. Given BioTelemetry's higher probable upside, research analysts plainly believe Beyond Air is more favorable than BioTelemetry.
In the previous week, BioTelemetry had 3 more articles in the media than Beyond Air. MarketBeat recorded 3 mentions for BioTelemetry and 0 mentions for Beyond Air. BioTelemetry's average media sentiment score of 0.00 equaled Beyond Air'saverage media sentiment score.
BioTelemetry received 345 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.25% of users gave Beyond Air an outperform vote while only 63.71% of users gave BioTelemetry an outperform vote.
BioTelemetry is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Beyond Air has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -1.22, meaning that its stock price is 222% less volatile than the S&P 500.
Summary
Beyond Air beats BioTelemetry on 7 of the 13 factors compared between the two stocks.
Get BioTelemetry News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioTelemetry Competitors List
Related Companies and Tools
